MedTrace Logo

Pilot Project of Virologic and Immunologic Correlates of GALT Immune Reconstitution Following Raltegravir Therapy

NCT00661960 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2017-05-30

Study results available
· View outcomes & findings →

Summary

This research is being done to study how the immune system in the small intestine improves after taking antiretroviral (anti-HIV) medications. The main purpose is to measure the increase in the numbers of immune cells in the intestine to see if one type of HIV medication gives different results than other types of HIV medications.

Conditions

  • HIV Infections
  • AIDS

Interventions

DRUG

raltegravir

400mg tablet twice daily by mouth for nine months

DRUG

efavirenz

600mg capsule once daily by mouth without regard to food

Sponsors & Collaborators

  • University of California, Davis

    lead OTHER

Principal Investigators

  • David M. Asmuth, M.D. · University of California, Davis

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2010-09-30
Completion
2011-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00661960 on ClinicalTrials.gov